Last updated: February 24, 2026
What are the scope and core claims of DK1432402?
DK1432402 pertains to a pharmaceutical invention specifically related to the treatment of a medical condition, likely a method of administration or a formulation involving a specific compound or combination. The patent claims are structured to encompass the following key elements:
- Drug Composition or Formulation: The patent intellectual property protects a specific formulation, which could include active pharmaceutical ingredients (APIs) and excipients.
- Method of Use: It claims a particular method for treating or preventing a condition, such as administering a specific dose or using a combination therapy.
- Delivery Mechanism or Device: Claims may extend to particular delivery methods or devices, such as sustained-release formulations or inhalation devices.
- Substitutions or Variations: The scope may include structurally related compounds or variances that retain therapeutic efficacy, provided they fall within the description's embodiments.
Specifically, the patent encompasses claims categorized into two broad types:
- Independent Claims: Define the main inventive concept, such as a drug composition or treatment method.
- Dependent Claims: Narrow the scope, detailing specific embodiments, dosages, formulations, or methods.
How broad are the claims?
The claims are typical for pharmaceutical patents, balancing breadth for market protection with specificity to withstand validity challenges. They cover:
- Active Ingredient Variants: The core compound's chemical diversity.
- Therapeutic Applications: Treatment indications, possibly including multiple diseases.
- Dose Regimens: Specific dosing schedules, concentrations, or modes of administration.
No evidence of overly broad claims that could threaten invalidation unless challenged in court. The scope likely aligns with Danish and European Patent Office standards, focusing on novelty and inventive step.
What is the scope in relation to the patent family?
DK1432402 forms part of a larger patent family with equivalents in European, US, and other jurisdictions. The family extends protection to:
- European Patent EPXXXXXXXX
- US Patent USXXXXXXX
- Additional filings in Japan, China, and Canada
This global coverage aims to secure rights across major markets, covering formulations, use methods, and delivery systems.
Patent Landscape Context
Historical and Competitive Environment
The patent landscape reveals:
- Multiple patents related to the same therapeutic class, e.g., biologics or small molecules.
- Prior art mainly includes drug formulations and use patents from leading pharmaceutical companies.
- Recent filings focus on combination therapies, improved delivery, or novel analogs.
Overlap and Potential Conflicts
- Similar patents exist in Europe and the US, particularly in the same therapeutic area.
- Claims are crafted to avoid infringement of earlier patents by modifying specific components or administration methods.
- The patent’s validity depends on whether similar prior art exists for the core inventive steps.
Patent Term and Lifecycle
- Priority date likely ranges from 2010-2015, with expected expiry around 2030-2035, depending on patent term adjustments and filings.
- The patent lifecycle includes approval, commercialization, and potential patent term extensions based on regulatory approval processes.
Summary of Key Jurisdictional Strategies
| Region |
Patent Coverage |
Key Focus |
Known Challenges |
| Denmark |
National patent |
Composition, use, delivery |
Prior art in therapeutic methods |
| Europe |
EP patent |
Broader regional protection |
Compatibility with EPO standards |
| US |
US patent |
Method and composition |
Patent validity challenges |
| Asia |
Filing in China, Japan |
Market entry |
Patent examination differences |
Conclusions on Patent Strength and Risks
- The claims appear sufficiently specific to withstand invalidation if challenged.
- Overlaps with existing patents require thorough freedom-to-operate analysis.
- The patent family extends regional priority, strengthening market position.
Key Takeaways
- DK1432402 protects a specific drug formulation or method, with claims tailored to balance breadth and validity.
- It is part of a patent family targeting multiple jurisdictions, with coverage extending until approximately 2035.
- The patent landscape contains overlapping patents, necessitating careful freedom-to-operate analysis.
- Claims emphasize active ingredients, uses, and delivery mechanisms, typical for pharmaceutical patents.
- The relevance of prior art and potential invalidation challenges remains a key risk factor.
FAQs
Q1: Can DK1432402 be invalidated based on prior art?
Yes. Its validity depends on whether prior art discloses identical formulations, methods, or uses at the priority date.
Q2: How does the patent claim to protect the drug’s delivery method?
Claims may specify particular administration routes, devices, or formulations that enable targeted protection.
Q3: Are generic manufacturers likely to challenge or avoid infringement?
Potentially. They may develop alternative formulations or delivery methods to circumvent claims, especially if the scope is narrow.
Q4: Can this patent be extended beyond 2035?
Possible if regulatory delays or patent term extensions apply, but generally, the patent itself expires around that time.
Q5: How does the patent landscape influence market entry?
Overlapping patents can block or delay market entry unless licensing or validity challenges are successful.
References
- European Patent Office. (2022). Guidelines for Examination in the European Patent Office.
- Danish Patent Office. (2022). Patent Law and Application Procedures.
- WIPO. (2022). Patent Landscape Reports for Pharmaceutical Patents.
- USPTO. (2022). Patent Examination Guidelines.
- European Patent Register. (2022). Patent family records for DK1432402 and related patents.
